Compare CTRE & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTRE | BIO |
|---|---|---|
| Founded | 2013 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.0B |
| IPO Year | 2013 | 1994 |
| Metric | CTRE | BIO |
|---|---|---|
| Price | $39.05 | $387.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $42.40 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 1.8M | 251.5K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | 96.25 | ★ 142.61 |
| EPS | ★ 0.74 | N/A |
| Revenue | $476,393,000.00 | ★ $2,583,200,000.00 |
| Revenue This Year | $5.97 | $2.74 |
| Revenue Next Year | $13.39 | $3.20 |
| P/E Ratio | $53.19 | ★ N/A |
| Revenue Growth | ★ 60.79 | 0.65 |
| 52 Week Low | $32.79 | $236.73 |
| 52 Week High | $43.62 | $396.23 |
| Indicator | CTRE | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 75.57 |
| Support Level | $38.28 | $289.16 |
| Resistance Level | $40.12 | N/A |
| Average True Range (ATR) | 0.78 | 11.00 |
| MACD | -0.00 | 1.25 |
| Stochastic Oscillator | 55.06 | 79.98 |
CareTrust REIT Inc is a self-administered, publicly traded REIT engaged in the ownership, acquisition, financing, development, and leasing of skilled nursing, seniors housing, and other healthcare-related properties. The company has one reportable segment consisting of investments in healthcare-related real estate assets. It generates revenues by leasing healthcare-related properties to healthcare operators under triple-net lease arrangements, in which the tenant is solely responsible for property-related costs. The company operates in Domestic and Foreign markets, with the majority of revenue coming from Domestic operations.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.